Chinook Is Advancing Kidney Disease Goals With Surrogate Endpoints, Asian JV

18 Feb 2022

Vancouver biotech is building a pipeline of candidates for rare, severe chronic kidney disease. It has an oral drug in Phase III and an antibody candidate in mid-stage development for IGA nephropathy.

Human Kidneys, 2d rendering — Chinook aims to offer precision kidney medicine on an international basis

Chinook Therapeutics, Inc. is developing a pair of drugs – an oral tablet and a monoclonal antibody – for IgA nephropathy, with potentially pivotal data expected for the oral drug in 2023. The Vancouver biotech has also garnered attention with an Asian joint venture that could provide entry to a region with a high prevalence of IgAN with limited capital and execution risk.

The company emerged in 2019 from the Versant Ventures incubator Inception Sciences, with a focus on precision medicine for chronic...